ReviewPsychoradiology2026
Neuroimaging evidence of mitochondrial dysfunction and inflammation in psychiatric disorders: a review.
Review in Psychoradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitochondrial dysfunction and neuroinflammation are two fundamental pathological processes underlying the development of psychiatric disorders. These processes are interconnected and may jointly contribute to disease progression. This article systematically reviews the progress of multimodal imaging approaches for assessing mitochondrial function, including magnetic resonance spectroscopy, PET tracers targeting mitochondrial complexes, MRI-based cerebral metabolic rate of oxygen, and emerging techniques such as T1ρ imaging and manganese-enhanced MRI, as well as neuroinflammation, including translocator protein (TSPO) PET, monoamine oxidase B PET, novel tracers targeting C3aR/IL-1β, and diffusion imaging techniques reflecting white matter microstructural alterations. These approaches have been applied to various psychiatric disorders, including schizophrenia, major depressive disorder, bipolar disorder, post-traumatic stress disorder, autism spectrum disorder, sleep disorders, and substance use disorders. Based on imaging evidence across different psychiatric disorders and cohorts, this review summarizes three transdiagnostic imaging features: impaired mitochondrial energy metabolism, alterations in glial cell immune status, and white matter microstructural alterations associated with neuroinflammation. However, although individual imaging techniques have independently identified mitochondrial dysfunction and neuroinflammation, few studies have applied dual-target imaging within the same research cohort. The direct relationship between these processes remains unverified by
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.